These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 36106755)
21. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Nicolatou-Galitis O; Schiødt M; Mendes RA; Ripamonti C; Hope S; Drudge-Coates L; Niepel D; Van den Wyngaert T Oral Surg Oral Med Oral Pathol Oral Radiol; 2019 Feb; 127(2):117-135. PubMed ID: 30393090 [TBL] [Abstract][Full Text] [Related]
22. Management of Medication-Related Osteonecrosis of the Jaw. Williams WB; O'Ryan F Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):517-25. PubMed ID: 26515735 [TBL] [Abstract][Full Text] [Related]
23. [Progress on medication-related osteonecrosis of the jaw]. Wang QZ; Liu JY; Pan J Hua Xi Kou Qiang Yi Xue Za Zhi; 2018 Oct; 36(5):568-572. PubMed ID: 30465354 [TBL] [Abstract][Full Text] [Related]
24. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ). Fusco V; Campisi G; Bedogni A Support Care Cancer; 2022 Sep; 30(9):7047-7051. PubMed ID: 35312858 [TBL] [Abstract][Full Text] [Related]
25. A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients. Jung S; Kim J; Park JH; Kim KY; Kim HJ; Park W Sci Rep; 2022 May; 12(1):8641. PubMed ID: 35606457 [TBL] [Abstract][Full Text] [Related]
26. Medication-related osteonecrosis of the jaw: A literature review. Kuroshima S; Sasaki M; Sawase T J Oral Biosci; 2019 Jun; 61(2):99-104. PubMed ID: 31109863 [TBL] [Abstract][Full Text] [Related]
27. Impacts of bisphosphonates on the bone and its surrounding tissues: mechanistic insights into medication-related osteonecrosis of the jaw. Srivichit B; Thonusin C; Chattipakorn N; Chattipakorn SC Arch Toxicol; 2022 May; 96(5):1227-1255. PubMed ID: 35199244 [TBL] [Abstract][Full Text] [Related]
28. Update MRONJ and perspectives of its treatment. Voss PJ; Poxleitner P; Schmelzeisen R; Stricker A; Semper-Hogg W J Stomatol Oral Maxillofac Surg; 2017 Sep; 118(4):232-235. PubMed ID: 28697987 [TBL] [Abstract][Full Text] [Related]
29. A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis. Campisi G; Mauceri R; Bertoldo F; Fusco V; Bedogni A Head Face Med; 2021 Jul; 17(1):25. PubMed ID: 34243807 [TBL] [Abstract][Full Text] [Related]
30. Medication-related osteonecrosis of the jaw: A disease of significant importance for older patients. Boston B; Ipe D; Capitanescu B; Gresita A; Hamlet S; Love R; Hadjiargyrou M; Huang CL; Nusem I; Miroiu RI; Popa-Wagner A; Warnke PH; Petcu EB J Am Geriatr Soc; 2023 Aug; 71(8):2640-2652. PubMed ID: 37224415 [TBL] [Abstract][Full Text] [Related]
31. Sclerotic bone: a sign of bone reaction in patients with medication related osteonecrosis of the jaw. Obermeier KT; Dewenter I; Malenova Y; Fliefel R; Kaeppler G; Otto S Sci Rep; 2024 Apr; 14(1):7914. PubMed ID: 38575664 [TBL] [Abstract][Full Text] [Related]
32. Antiresorptive Agents and Anti-Angiogenesis Drugs in the Development of Osteonecrosis of the Jaw. Allegra A; Innao V; Pulvirenti N; Musolino C Tohoku J Exp Med; 2019 May; 248(1):27-29. PubMed ID: 31080196 [TBL] [Abstract][Full Text] [Related]
33. Medication-related osteonecrosis of the jaw-like lesions in rodents: A comprehensive systematic review and meta-analysis. Kuroshima S; Sasaki M; Murata H; Sawase T Gerodontology; 2019 Dec; 36(4):313-324. PubMed ID: 31373407 [TBL] [Abstract][Full Text] [Related]
34. Denosumab-related osteonecrosis of the jaw following non-surgical periodontal therapy: A case report. Diniz-Freitas M; Fernández-Feijoo J; Diz Dios P; Pousa X; Limeres J J Clin Periodontol; 2018 May; 45(5):570-577. PubMed ID: 29479739 [TBL] [Abstract][Full Text] [Related]
35. The Prevention of Medication-related Osteonecrosis of the Jaw. Poxleitner P; Engelhardt M; Schmelzeisen R; Voss P Dtsch Arztebl Int; 2017 Feb; 114(5):63-69. PubMed ID: 28241916 [TBL] [Abstract][Full Text] [Related]
36. Medication-Related Osteonecrosis of the Jaw (MRONJ): Are Antiresorptive Drugs the Main Culprits or Only Accomplices? The Triggering Role of Vitamin D Deficiency. Dalle Carbonare L; Mottes M; Valenti MT Nutrients; 2021 Feb; 13(2):. PubMed ID: 33567797 [TBL] [Abstract][Full Text] [Related]
37. Infection and medication-related osteonecrosis of the jaw. Katsarelis H; Shah NP; Dhariwal DK; Pazianas M J Dent Res; 2015 Apr; 94(4):534-9. PubMed ID: 25710950 [TBL] [Abstract][Full Text] [Related]
38. Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab. Wick A; Bankosegger P; Otto S; Hohlweg-Majert B; Steiner T; Probst F; Ristow O; Pautke C Clin Oral Investig; 2022 Mar; 26(3):2839-2852. PubMed ID: 34812959 [TBL] [Abstract][Full Text] [Related]
39. Case series of medication-related osteonecrosis of the jaw (MRONJ) patients prescribed a drug holiday. Hamid A; Thomas S; Bell C; Gormley M Br J Oral Maxillofac Surg; 2023 Apr; 61(3):227-232. PubMed ID: 36935312 [TBL] [Abstract][Full Text] [Related]
40. Medication-related osteonecrosis of the jaw: A multifaceted diagnostic challenge. Mini review. Bonachea R; Katz J Am J Dent; 2022 Apr; 35(2):109-112. PubMed ID: 35506967 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]